Bismuth-212 radiopharmaceutical

Drug Profile

Bismuth-212 radiopharmaceutical

Alternative Names: Bi-212 melanocortin alpha

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Missouri System
  • Developer AlphaMed
  • Class Drug conjugates; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Malignant melanoma

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Malignant-melanoma in USA
  • 09 May 2008 AlphaMed Inc receives a peer review grant from the National Cancer Institute for the development of the Bismuth-212 radiopharmaceutical for Malignant melanoma
  • 01 Aug 2005 A preclinical study has been added to the adverse events, pharmacokinetics and Cancer pharmacodynamics sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top